Targeting Plk1 to enhance efficacy of Olaparib in castration-resistant prostate cancer

Olaparib is a FDA-approved PARP inhibitor (PARPi) that has shown promise as a synthetic lethal treatment approach for BRCA-mutant castration-resistant prostate cancer (CRPC) in clinical use. However, emerging data has also shown that even BRCA-mutant cells may be resistant to PARPi. The mechanistic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Li, Jie, Wang, Ruixin, Kong, Yifan, Broman, Meaghan M., Carlock, Colin, Chen, Long, Li, Zhiguo, Farah, Elia, Ratliff, Timothy L., Liu, Xiaoqi
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5337144/
https://ncbi.nlm.nih.gov/pubmed/28069876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0361
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi